At a glance
ClinicalIndex Comparison RecordN/ACompleted· 23 enrolled
Drug / intervention
POM3 +1 moredrug
Likely dose
POM3 4 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Acid Ethyl Esters on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
In Brief
A clinical study evaluating POM3 and Placebo for Hypertriglyceridemia. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The objectives of this study are to assess the effects of 4 g/d prescription omega-3 acid ethyl esters (POM3), compared with a placebo, on indices of insulin sensitivity and secretion, as well as aspects of the fasting and postprandial lipid and lipoprotein profiles, in subjects with hypertriglyceridemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartMar 2010
Primary CompletionDec 2010
Study CompletionFeb 2011
TodayJul 2026
First PostedDec 17, 2009
Enrollment StartMar 1, 2010
Primary CompletionDec 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.5 years ago
Interventions
POM3drug
4 g/day
Placebodrug
matching placebo capsule, 4 g/day